T. Rowe Price Investment Management, Inc. Moon Lake Immunotherapeutics Transaction History
T. Rowe Price Investment Management, Inc.
- $163 Billion
- Q1 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 1,095,101 shares of MLTX stock, worth $44.5 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
1,095,101
Previous 1,220,602
10.28%
Holding current value
$44.5 Million
Previous $73.7 Million
25.38%
% of portfolio
0.03%
Previous 0.05%
Shares
4 transactions
Others Institutions Holding MLTX
# of Institutions
135Shares Held
56MCall Options Held
379KPut Options Held
402K-
Bvf Inc San Francisco, CA21.8MShares$884 Million32.73% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$345 Million24.56% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.58MShares$105 Million1.56% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.31MShares$93.9 Million0.02% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.28MShares$92.9 Million0.23% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.5B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...